Author Correction: Randomized Evaluation of Anagliptin vs Sitagliptin On low-density lipoproteiN cholesterol in diabetes (REASON) Trial: A 52-week, open-label, randomized clinical trial

Takeshi Morimoto; Ichiro Sakuma; Mio Sakuma; Akihiro Tokushige; Masahiro Natsuaki; Tomohiro Asahi; Michio Shimabukuro; Takashi Nomiyama; Osamu Arasaki; Koichi Node; Shinichiro Ueda

首页> 外文期刊>Scientific reports. >Author Correction: Randomized Evaluation of Anagliptin vs Sitagliptin On low-density lipoproteiN cholesterol in diabetes (REASON) Trial: A 52-week, open-label, randomized clinical trial

【24h】

Author Correction: Randomized Evaluation of Anagliptin vs Sitagliptin On low-density lipoproteiN cholesterol in diabetes (REASON) Trial: A 52-week, open-label, randomized clinical trial

机译：作者矫正：Anagliptin的随机评估Anagliptin对低密度脂蛋白胆固醇的糖尿病（原因）试验：A 52周，开放标签，随机临床试验

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Tis Article contains errors. Te calculation method of LDL-C, presented in Figure 2 and 3 is described as beingbased on the Friedewald (F) equation. However, the data presented was calculated based on the direct method.

机译：TIS文章包含错误。图2和3中呈现的LDL-C的TE计算方法被描述为在Friedewald（F）方程上被缩小。但是，所呈现的数据是基于直接方法计算的。

著录项

来源
《Scientific reports.》 |2020年第1期|共2页
作者
Takeshi Morimoto; Ichiro Sakuma; Mio Sakuma; Akihiro Tokushige; Masahiro Natsuaki; Tomohiro Asahi; Michio Shimabukuro; Takashi Nomiyama; Osamu Arasaki; Koichi Node; Shinichiro Ueda;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Dissimilar Effects of Anagliptin and Sitagliptin on Lipoprotein Subclass in Standard or Strong Statin-Treated Patients with Type-2 Diabetes Mellitus: A Subanalysis of the REASON (Randomized Evaluation of Anagliptin versus Sitagliptin on Low-Density LipoproteiN Cholesterol in Diabetes) Trial [J] . Progress in Artificial Intelligence . 2020,第1期

机译：Anagliptin和SitaGliptin对2型糖尿病患者脂蛋白亚类对脂蛋白亚类的不同影响MELLITUS：对糖尿病低密度脂蛋白胆固醇对SINAGLIPTIN对SITAGLIPTIN的随机评价）试验的药物分析
2. Effect of Anagliptin and Sitagliptin on Low-Density Lipoprotein Cholesterol in Type 2 Diabetic Patients with Dyslipidemia and Cardiovascular Risk: Rationale and Study Design of the REASON Trial [J] . Shinichiro Ueda, Michio Shimabukuro, Osamu Arasaki, Cardiovascular drugs and therapy . 2018,第1期

机译：Anagliptin和SitaGliptin对2型糖尿病患者低密度脂蛋白胆固醇血吸虫和心血管风险的影响：理论及研究设计原因试验
3. Anagliptin and sitagliptin as add-ons to metformin for patients with type 2 diabetes: a 24-week, multicentre, randomized, double-blind, active-controlled, phase III clinical trial with a 28-week extension [J] . Jin S. -M., Park S. W., Yoon K. -H., Diabetes, obesity & metabolism . 2015,第5期

机译：安那列汀和西他列汀作为2型糖尿病患者二甲双胍的附加药物：一项为期24周，多中心，随机，双盲，主动控制的III期临床试验，延长了28周
4. Non-randomized clinical trial of Ambulatory Coronary Angioplasty - The ACA Trial - [C] . Telayna J.M., Costantini R.A., García C., World Congress on Heart Disease . 2012

机译：非随机化临床试验的动态冠状动脉血管成形术 - ACA试验 -
5. The effect of exercise training intensity on physical fitness and physical function in people with type 2 diabetes: A randomized clinical trial. [D] . Mathis, Ruth Ann. 2013

机译：运动训练强度对2型糖尿病患者身体素质和身体功能的影响：一项随机临床试验。
6. Randomized Evaluation of Anagliptin vs Sitagliptin On low-density lipoproteiN cholesterol in diabetes (REASON) Trial: A 52-week open-label randomized clinical trial [O] . Takeshi Morimoto, Ichiro Sakuma, Mio Sakuma, -1

机译：Anagliptin vs Sitagliptin对糖尿病低密度脂蛋白胆固醇的随机评估（REASON）试验：一项为期52周的开放标签随机临床试验
7. Randomized Evaluation of Anagliptin vs Sitagliptin On low-density lipoproteiN cholesterol in diabetes (REASON) Trial: A 52-week, open-label, randomized clinical trial [O] . Takeshi Morimoto, Ichiro Sakuma, Mio Sakuma, 2019

机译：Anagliptin对糖尿病低密度脂蛋白胆固醇的Anagliptin Vs SitaGliptin的随机评估（原因）试验：52周，开放式标记，随机临床试验

Author Correction: Randomized Evaluation of Anagliptin vs Sitagliptin On low-density lipoproteiN cholesterol in diabetes (REASON) Trial: A 52-week, open-label, randomized clinical trial

摘要

著录项

相似文献

相关主题

期刊订阅